Transdermal Delivery Formulations
Summary
USPTO published patent application US20260090981A1 for LifeActive, Inc., covering transdermal delivery formulations combining weak organic acids with fatty acid microemulsions for epicutaneous administration of therapeutic agents, drugs, and nutrients. The formulations are designed for use in high humidity conditions such as showers or saunas.
What changed
USPTO published patent application US20260090981A1 (Application No. 19411114, filed December 5, 2025) for LifeActive, Inc. The application discloses transdermal delivery formulations comprising a homogeneous mixture of a transdermal accelerant (weak organic acid with pKa greater than 2.0) and a microemulsion (nonionic emulsifier, water, cis-unsaturated long-chain fatty acid). The formulations create fatty acid micelles and liposomes for encapsulating drugs, nutrients, or therapeutic compounds, with pH typically ranging from 1.5 to 2.5.
This is a patent application publication providing intellectual property notice. No compliance actions, deadlines, or penalties are associated with this document. Entities developing transdermal delivery technologies may wish to conduct freedom-to-operate analyses to assess potential infringement risks. Patent prosecution timelines vary and do not create regulatory obligations.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRANSDERMAL DELIVERY FORMULATIONS
Application US20260090981A1 Kind: A1 Apr 02, 2026
Assignee
LifeActive, Inc.
Inventors
Calvin Dexter MORRIS, Burgess A. THOMASSON, JR., Scott A. JENKINS
Abstract
Provided are transdermal delivery formulations, and methods for the manufacture thereof, for the epicutaneous administration of therapeutic agents, drugs, and nutrients to human subjects; veterinary animals; domesticated or undomesticated animals, plants or insects; or agricultural animals, plants, or insects. Transdermal delivery formulations disclosed herein comprise a homogenous mixture of (a) a transdermal accelerant comprising a weak organic acid having a pKa greater than 2.0 and (b) a microemulsion comprising a nonionic emulsifier, water, and a cis-unsaturated long-chain fatty acid. Fatty acid microemulsions are combined with the acidified transdermal accelerants having a pH greater than 1.0 (typically from 1.5 to 2.5) to yield a homogenous transdermal delivery formulation comprising fatty acid micelles and/or liposomes that encapsulate one or more compound, such as a nutrient or a drug, and incorporate one or more cis-unsaturated fatty acid having a 12 to 26 carbon chain that includes one or more double bond in a cis configuration. Transdermal delivery formulations exhibit ideal solubility and absorption properties in high humidity conditions, such as in a warm to hot shower or sauna.
CPC Classifications
A61K 9/0014 A61K 9/1075 A61K 31/201 A61K 31/375 A61K 36/185 A61K 47/12 A61K 47/26
Filing Date
2025-12-05
Application No.
19411114
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.